Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TGA wants to raise age for OTC cough/cold products

This article was originally published in The Tan Sheet

Executive Summary

The Australian Therapeutic Goods Administration recommends raising the minimum age for OTC pediatric cough and cold products to 6 years - the same age 1U.K. regulators recommend and two years older than in the 2U.S. TGA bases the recommendation on an external safety review of data summarized in Australia's 3review of cough and cold medicines in children. It also wants the 4National Drugs and Poisons Schedule Committee to make cough and cold products for 6- to 12-year-olds available only from a pharmacist, and wants manufacturers to package all cough and cold products in child-resistant containers by July 2010

You may also be interested in...

U.K. To Move Kids’ Cough/Cold Drugs BTC, Redraws Age Recommendation

Manufacturers of pediatric cough/cold medicines sold in the U.K. have until March 2010 before the products must be sold behind the pharmacy counter, one of several measures to improve safe use

Standardize Wording, Dosing Devices of Pediatric Cold Products – NDAC

FDA advisory committees recommend not only standardizing language on OTC pediatric cough/cold product labels, but also dosing devices for the products

The EU’s New Batteries Regulation: When And How Its Requirements Will Impact Medtech

The EU Batteries Regulation is yet another legal instrument medical device manufacturers must address over the coming years alongside the core Medical Device and IVD Regulations.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts